Hypoparathyroidism after total thyroidectomy: reactive to symptoms supplementation

IF 1.6 3区 医学 Q2 SURGERY BMC Surgery Pub Date : 2024-09-14 DOI:10.1186/s12893-024-02534-9
Maxime Constant, Franck Schillo, Sophie Billet, Bruno Heyd, Alexandre Doussot, Nicolas Bouviez
{"title":"Hypoparathyroidism after total thyroidectomy: reactive to symptoms supplementation","authors":"Maxime Constant, Franck Schillo, Sophie Billet, Bruno Heyd, Alexandre Doussot, Nicolas Bouviez","doi":"10.1186/s12893-024-02534-9","DOIUrl":null,"url":null,"abstract":"After total thyroidectomy (TT), postoperative hypoparathyroidism (PH) is the most frequent complication. Yet, management strategies for PH remain disputed. The aim of this study was to evaluate outcomes of a reactive supplementation in case of symptomatic PH. Additionally, risk factors for symptomatic PH and readmission due to PH were analyzed. All consecutive patients who underwent TT or completion from 2017 to 2022 were considered for inclusion. During this period, a reactive to symptom vitamin-calcium supplementation was used. The primary outcome was the occurrence of severe PH after discharge resulting in readmission. Overall, 307 patients were included, of which 98 patients (31.9%) developed symptomatic PH including 43 patients before discharge. Independent risk factors for developing symptomatic PH were age (p = 0.010) and postoperative day 1 (POD1) PTH level (p < 0.001). Overall, 264 patients (86%) did not present PH before discharge and were discharged home. Among them, 55 patients (20.8%) experienced symptomatic PH, requiring readmission in 18 patients. The overall readmission rate owing to symptomatic PH requiring intravenous supplementation despite oral vitamin-calcium supplementation was 6.8% (n = 18). Independent risk factors for symptomatic PH-related readmission were age (p = 0.007) and POD1 PTH level (p < 0.001). Adequate cut-off values for predicting readmission were POD1 albumin-adjusted calcium = 2.1 mmol/l (Sensibility = 0.95, Specificity = 0.30) and POD1 PTH = 11.5 pg/ml (Sensibility = 0.90, Specificity = 0.71). Supplementing only symptomatic patients was safe and efficient. This attitude does not alter on morbidity, mortality or readmission rate which is in line with current literature.","PeriodicalId":49229,"journal":{"name":"BMC Surgery","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12893-024-02534-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

After total thyroidectomy (TT), postoperative hypoparathyroidism (PH) is the most frequent complication. Yet, management strategies for PH remain disputed. The aim of this study was to evaluate outcomes of a reactive supplementation in case of symptomatic PH. Additionally, risk factors for symptomatic PH and readmission due to PH were analyzed. All consecutive patients who underwent TT or completion from 2017 to 2022 were considered for inclusion. During this period, a reactive to symptom vitamin-calcium supplementation was used. The primary outcome was the occurrence of severe PH after discharge resulting in readmission. Overall, 307 patients were included, of which 98 patients (31.9%) developed symptomatic PH including 43 patients before discharge. Independent risk factors for developing symptomatic PH were age (p = 0.010) and postoperative day 1 (POD1) PTH level (p < 0.001). Overall, 264 patients (86%) did not present PH before discharge and were discharged home. Among them, 55 patients (20.8%) experienced symptomatic PH, requiring readmission in 18 patients. The overall readmission rate owing to symptomatic PH requiring intravenous supplementation despite oral vitamin-calcium supplementation was 6.8% (n = 18). Independent risk factors for symptomatic PH-related readmission were age (p = 0.007) and POD1 PTH level (p < 0.001). Adequate cut-off values for predicting readmission were POD1 albumin-adjusted calcium = 2.1 mmol/l (Sensibility = 0.95, Specificity = 0.30) and POD1 PTH = 11.5 pg/ml (Sensibility = 0.90, Specificity = 0.71). Supplementing only symptomatic patients was safe and efficient. This attitude does not alter on morbidity, mortality or readmission rate which is in line with current literature.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
甲状腺全切除术后甲状旁腺功能减退:对症状补充剂的反应
甲状腺全切除术(TT)后,术后甲状旁腺功能减退症(PH)是最常见的并发症。然而,PH的治疗策略仍存在争议。本研究旨在评估有症状的PH患者接受反应性补充治疗的效果。此外,还分析了无症状 PH 和因 PH 再入院的风险因素。所有在 2017 年至 2022 年期间接受过 TT 或完成 TT 的连续患者均被纳入考虑范围。在此期间,采用了反应性对症维生素钙补充剂。主要结果是出院后发生严重 PH 导致再次入院。总共纳入了 307 名患者,其中 98 名患者(31.9%)出现了有症状的 PH,包括出院前的 43 名患者。出现症状性 PH 的独立风险因素是年龄(P = 0.010)和术后第 1 天(POD1)PTH 水平(P < 0.001)。总体而言,264 名患者(86%)在出院前未出现 PH 并出院回家。其中,55 名患者(20.8%)出现有症状的 PH,18 名患者需要再次入院。尽管口服了维生素钙补充剂,但由于出现需要静脉补充的症状性 PH 而再次入院的总比例为 6.8%(n = 18)。年龄(p = 0.007)和 POD1 PTH 水平(p < 0.001)是无症状 PH 相关再入院的独立风险因素。预测再入院的适当临界值为 POD1 白蛋白调整钙 = 2.1 mmol/l(灵敏度 = 0.95,特异性 = 0.30)和 POD1 PTH = 11.5 pg/ml(灵敏度 = 0.90,特异性 = 0.71)。仅对有症状的患者进行补充是安全有效的。这种态度不会改变发病率、死亡率或再入院率,这与当前的文献一致。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
BMC Surgery
BMC Surgery SURGERY-
CiteScore
2.90
自引率
5.30%
发文量
391
审稿时长
58 days
期刊介绍: BMC Surgery is an open access, peer-reviewed journal that considers articles on surgical research, training, and practice.
期刊最新文献
Real-world study on the application of enhanced recovery after surgery protocol in video-assisted thoracoscopic day surgery for pulmonary nodule resection. The seven-day cumulative post-esophagectomy inflammatory response predicts cancer recurrence. Seprafilm® and adhesive small bowel obstruction in colorectal/abdominal surgery: an updated systematic review. The safety and efficacy of stapler method for transection of the pancreatic parenchyma during pancreatoduodenectomy (STRAP-PD trial): study protocol for a randomized control trial. Challenges and opportunities for Mohs surgery implementation in African healthcare systems.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1